Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een onderzoek om bijwerkingen te beoordelen en te bestuderen hoe intraveneus (IV) pivekimab sunirine zich door het lichaam verplaatst bij pediatrische deelnemers met recidiverende of refractaire acute myeloïde leukemie (AML)

1 oktober 2026 bijgewerkt door: AbbVie

Een Fase 1b-studie naar de veiligheid en farmacokinetiek van Pivekimab Sunirine bij pediatrische patiënten met recidiverend of refractair acuut myeloïde leukemie (AML)

Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment. This study will assess the adverse events and how pivekimab sunirine moves through the body in pediatric participants with relapsed or refractory (R/R) AML.

Pivekimab sunirine is a drug being evaluated in the treatment of AML. This is an open label, single arm study, participants will be enrolled in 1 of the 3 cohorts based on their age and will receive pivekimab sunirine at a dose based on their weight. Around 18 pediatric participants with a diagnosis of AML will be enrolled in the study at approximately 30 sites around the world.

Participants will receive intravenous (IV) pivekimab sunirine alone. The total study duration is approximately 28 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.

Studie Overzicht

Toestand

Werving

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

18

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • New South Wales
      • Westmead, New South Wales, Australië, 2145
        • Werving
        • The Children's Hospital at Westmead /ID# 275672
    • Western Australia
      • Perth, Western Australia, Australië, 6009
        • Werving
        • Perth Children'S Hospital /ID# 275673
      • Paris, Frankrijk, 75571
        • Werving
        • Hopital Armand Trousseau /ID# 276231
    • New Aquitaine
      • Bordeaux, New Aquitaine, Frankrijk, 33076
        • Werving
        • Chu Bordeaux - Hopital Pellegrin /ID# 277645
    • Roma
      • Rome, Roma, Italië, 00165
        • Werving
        • Ospedale Pediatrico Bambino Gesu /ID# 275692
      • Taipei, Taiwan, 100
        • Werving
        • National Taiwan University Hospital /ID# 276635
    • Cambridgeshire
      • Cambridge, Cambridgeshire, Verenigd Koninkrijk, CB2 0QQ
        • Werving
        • Cambridge University Hospital /ID# 277041
    • California
      • Palo Alto, California, Verenigde Staten, 94304
        • Werving
        • Lucile Packard Children's Hospital /ID# 276015
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30329
        • Werving
        • Children'S Healthcare Of Atlanta - Arthur M. Blank Hospital /ID# 275740
    • New York
      • Valhalla, New York, Verenigde Staten, 10595
        • Werving
        • New York Medical College /ID# 275597
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37203
        • Werving
        • Tristar Centennial Medical Center /ID# 275831
    • Texas
      • Dallas, Texas, Verenigde Staten, 75235
        • Werving
        • Children's Medical Center Dallas /ID# 275930
    • Seoul Teugbyeolsi
      • Seoul, Seoul Teugbyeolsi, Zuid -Korea, 03080
        • Werving
        • Seoul National University Hospital /ID# 276978
      • Seoul, Seoul Teugbyeolsi, Zuid -Korea, 06351
        • Werving
        • Samsung Medical Center /ID# 276979

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

6 maanden tot 17 jaar (Kind)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Must have histologically confirmed acute myeloid leukemia (AML) meeting one of the following disease criteria:

    • Second or greater relapse. OR
    • Disease refractory to second or subsequent line of therapy (defined as resistant disease after at least one cycle of each treatment regimen).
  • Must have myeloid leukemic blasts that are CD123-positive by flow cytometry as determined by the treating institution.

  • Has >= 5% myeloid leukemic blasts in bone marrow at time of relapse or refractory disease and prior to Screening for this study.

  • Performance status by Lansky (< 16 years old at evaluation) or Karnofsky (>= 16 years old at evaluation) score >= 50 or ECOG score <= 2.

  • May have status of central nervous system (CNS)1, CNS2, or CNS3 disease without clinical signs or neurologic symptoms suggestive of CNS leukemia, such as facial nerve palsy, brain/eye involvement or hypothalamic syndrome. Participants receiving intrathecal therapy and no additional CNS-directed systemic therapy at study entry are eligible and may continue treatment as clinically indicated in accordance with institutional practice.

  • For those participants who have not reached the age of consent, parent or legal guardian with the willingness and ability to provide informed consent and participant willing and able to give assent, as appropriate for age and country.

Exclusion Criteria:

  • Known clinically significant cardiac disease.
  • Down syndrome.
  • Acute promyelocytic leukemia (APL) or juvenile myelomonocytic leukemia (JMML).
  • Symptomatic central nervous system (CNS3) disease
  • Prior history of any severity veno-occlusive disease/sinusoidal obstructive syndrome (VOD/SOS) of the liver.
  • Prior history of hematopoietic stem cell transplant within 6 months prior to Screening without evidence of active GvHD at the time of screening and the participant is off medications to treat or prevent either post-transplant graft-versus-host disease (GvHD) or post-transplant rejection (except for a stable dose of corticosteroids).
  • Have received prior Chimeric Antigen Receptor T-cell (CAR-T) therapy.
  • Any other known current malignancy requiring therapy.
  • Currently receiving anticancer therapy with antineoplastic intent, including radiotherapy, systemic therapy small molecules, monoclonal antibodies, other investigational agents, or high-dose chemotherapy with the exception of intrathecal therapy.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Cohort 1: Pivekimab Sunirine Ages 2 to < 6 Years

Participants will receive pivekimab sunirine, as part of the approximately 28 month study duration. If enrolled, subjects aged 6 months to less than 2 years will be included in Cohort 1

Intravenous

Experimenteel: Cohort 2: Pivekimab Sunirine Ages 6 to < 12 Years

Participants will receive pivekimab sunirine, as part of the approximately 28 month study duration.

Intravenous

Experimenteel: Cohort 3: Pivekimab Sunirine Ages 12 to < 17 Years

Participants will receive pivekimab sunirine, as part of the approximately 28 month study duration.

Intravenous

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Leading to Treatment Discontinuation
Tijdsspanne: Up to Approximately 24 Months

Number of participants with protocol specified Treatment-Emergent Adverse Events (TEAEs) during and after treatment with pivekimab sunirine (PVEK). Severity of TEAEs will be graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.

Up to Approximately 24 Months
Maximum Observed Serum/Plasma Concentration (Cmax) of Intact Antibody-Drug Conjugate (ADC)
Tijdsspanne: Up to Approximately 22 Months

Maximum observed serum/plasma concentration of intact ADC.

Up to Approximately 22 Months
Cmax of FGN849 Payload
Tijdsspanne: Up to Approximately 22 Months

Maximum observed serum/plasma concentration of FGN849 payload.

Up to Approximately 22 Months
Area Under the Concentration-Time Curve (AUC) of Intact ADC
Tijdsspanne: Up to Approximately 22 Months

Area under the concentration-time curve of intact ADC.

Up to Approximately 22 Months
AUC of FGN849 payload
Tijdsspanne: Up to Approximately 22 Months

Area under the concentration-time curve of FGN849 payload.

Up to Approximately 22 Months
Time to Cmax (Tmax) of Intact ADC
Tijdsspanne: Up to Approximately 22 Months

Time to Cmax of intact ADC.

Up to Approximately 22 Months
Tmax of FGN849 Payload
Tijdsspanne: Up to Approximately 22 Months

Time to Cmax of payload.

Up to Approximately 22 Months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants Achieving Complete Remission (CR)
Tijdsspanne: Up to Approximately 28 Months

CR is defined as Hematologic recovery: Absolute Neutrophil Count (ANC) > 1.0 × 10^9/L (> 1,000/μL) and platelet count > 100 × 10^9/L (> 100,000/μL); < 5% bone marrow blasts; absence of circulating blasts; no evidence of extramedullary disease; no transfusions or support by exogenous growth factors (GCSF) within 7 days prior to response evaluation.

Up to Approximately 28 Months
Percentage of Participants Achieving Composite Complete Remission (CR + complete remission with incomplete recovery [CRi])
Tijdsspanne: Up to Approximately 28 Months

Percentage of participants achieving CR + CRi.

Up to Approximately 28 Months
Percentage of Participants Achieving Composite Complete Remission (CR + complete remission with partial hematological [CRh])
Tijdsspanne: Up to Approximately 28 Months

Percentage of participants achieving CR + CRh.

Up to Approximately 28 Months
Duration of Complete Remission (DOCR)
Tijdsspanne: Up to Approximately 28 Months

DOCR is defined as the first response of CR to the time of relapse or death from any cause, whichever comes first; for participants who did not relapse or die, the duration will be censored at the time of the last response assessment.

Up to Approximately 28 Months
Duration of Composite Complete Remission (CR + CRi)
Tijdsspanne: Up to Approximately 28 Months

Duration of composite complete remission (CR + CRi).

Up to Approximately 28 Months
Duration of Composite Complete Remission (CR + CRh)
Tijdsspanne: Up to Approximately 28 Months

Duration of composite complete remission (CR + CRh).

Up to Approximately 28 Months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: ABBVIE INC., AbbVie

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

20 mei 2026

Primaire voltooiing (Geschat)

1 april 2028

Studie voltooiing (Geschat)

1 maart 2030

Studieregistratiedata

Eerst ingediend

15 december 2025

Eerst ingediend dat voldeed aan de QC-criteria

15 december 2025

Eerst geplaatst (Werkelijk)

29 december 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

5 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

1 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren